Impact News +++ FDA-Schnellverfahren für Norovirus-Mittel treibt Aktie von Cocrystal Pharma an (Investing.com DE) +++ COCRYSTAL Aktie -3,15%

CONTEXT THERAPEUTICS Aktie

>Aktienkurs

2.56 EUR +11.3% (TradegateBSX)

Ask: 2.46 EUR / 1100 Stück

Bid: 2.4 EUR / 1100 Stück

Tagesumsatz: 18606 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>Performance

1 Woche: -0,4%

1 Monat: +19,9%

3 Monate: +120,2%

6 Monate: +176,7%

1 Jahr: +338,3%

laufendes Jahr: +120,2%

>CONTEXT THERAPEUTICS Aktie

Name:

CONTEXT THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US21077P1084 / A3CWBU

Symbol/ Ticker:

6K9 (Frankfurt) / CNTX (NASDAQ)

Kürzel:

FRA:6K9, ETR:6K9, 6K9:GR, NASDAQ:CNTX

Index:

Webseite:

https://www.contexttherap..

Profil:

Context Therapeutics Inc. is a biopharmaceutical company focused on advancing treatments for hormone-driven female cancers. Primarily, the company develops investigational therapies targeting estrogen receptors, aiming to innovate in areas of signifi..
>Volltext..

Marktkapitalisierung:

194.63 Mio. EUR

Unternehmenswert:

139.04 Mio. EUR

Umsatz:

EBITDA:

-34.29 Mio. EUR

Nettogewinn:

-31.23 Mio. EUR

Gewinn je Aktie:

-0.33 EUR

Schulden:

0.1 Mio. EUR

Liquide Mittel:

57.06 Mio. EUR

Operativer Cashflow:

-22.81 Mio. EUR

Bargeldquote:

8.23

Umsatzwachstum:

Gewinnwachstum:

-19.14%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CONTEXT THERAPEUTICS, CONTEXT THERAPEUTIC

Letzte Datenerhebung:

02.04.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 91.88 Mio. St.

Frei handelbar: 70.74%

Leerverk. Aktien: 1.4%

Rückkaufquote: 0.01%

Mitarbeiter: 15

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 158.66%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 3.64

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -43.36%

Eigenkaprendite: -46.39%

>Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>Chart & Kurs - NASDAQ

>Alle News

02.04.26 - 17:30	Context Therapeutics rises on FDA fast track status for lead asset (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

02.04.26 - 13:33	Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer (GlobeNewswire EN)
	Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC...

23.03.26 - 21:27	Context Therapeutics GAAP EPS of -$0.38 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.03.26 - 21:18	Context Therapeutics Reports Full Year 2025 Operating and Financial Results (GlobeNewswire EN)
	Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026...

19.03.26 - 12:33

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire EN)

PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA. The presentation will highlight preclinical data regarding the Company's asset, CT-202, a Nectin-4 x CD3 TCE....

09.02.26 - 13:33	Context Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its participation in several upcoming investor conferences....

16.01.26 - 22:09

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context....

06.01.26 - 03:30	After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains (RTTNews)
	Several biotechnology and pharmaceutical names posted notable gains in after-hours trading on Monday, driven by clinical trial updates, regulatory progress, and investor anticipation ahead of key data releases....

07.11.25 - 13:33

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting (GlobeNewswire EN)

PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two posters discussing the Company's CT-95 and CT-202 programs at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, being held November 7–9, 2025 in National Harbor, MD....

06.11.25 - 15:24	Context Therapeutics GAAP EPS of -$0.10 misses by $0.01 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 22:18	Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results (GlobeNewswire EN)
	Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety...

28.10.25 - 12:33	Context Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	PHILADELPHIA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its participation in two upcoming investor conferences....

06.10.25 - 13:33

Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer′s (SITC) 40th Annual Meeting (GlobeNewswire EN)

PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced two posters will be presented at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, being held November 7–9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, MD....

03.10.25 - 22:18

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase 30,000 shares of its common stock to a new employee as an inducement material for accepting employment with Context....

27.08.25 - 13:33	Context Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
	PHILADELPHIA, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that the Company will participate in the following investor conferences:...

07.08.25 - 17:36	Context Therapeutics reports Q2 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.08.25 - 22:15	Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results (GlobeNewswire EN)
	CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing...

11.06.25 - 01:02	Insiderhandel: Chief Legal Officer, Corp. Sec kauft Aktien von Context Therapeutics im Wert von 11520 USD (Insiderkauf)
	Levit, Alex C. - Vorstand - Tag der Transaktion: 2025-06-06...

11.06.25 - 01:02	Insiderhandel: Chief Financial Officer kauft Aktien von Context Therapeutics im Wert von 25486 USD (Insiderkauf)
	Minai-Azary, Jennifer Lynn - Vorstand - Tag der Transaktion: 2025-06-06...

11.06.25 - 01:02	Insiderhandel: Chief Executive Officer kauft Aktien von Context Therapeutics im Wert von 70080 USD (Insiderkauf)
	Lehr, Martin A. - Vorstand - Tag der Transaktion: 2025-06-09...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Don′t marry, be happy. - Hera Lind

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram